Risk Factors of Peripheral Neuropathy in Diabetic and Non-Diabetic Populations: A Systematic Review
DOI:
https://doi.org/10.26630/jk.v17i2.5388Keywords:
Chemotherapy-induced peripheral neuropathy, Diabetes mellitus, Glycemic control, Hypertension, Metabolic syndromeAbstract
Peripheral neuropathy (PN) is a common neurological complication associated with substantial morbidity, disability, and reduced quality of life. Although numerous studies have identified risk factors for PN, findings remain heterogeneous across diabetic and non-diabetic populations, and comprehensive evidence synthesizing these determinants, particularly in the Indonesian context, is still limited. This study aims to identify and compare the major risk factors associated with peripheral neuropathy in diabetic and non-diabetic populations through a systematic literature review. A systematic review was conducted in accordance with PRISMA guidelines. Literature searches were performed in PubMed and Google Scholar using keywords related to peripheral neuropathy and risk factors. Articles published between 2020 and 2025 in English or Indonesian were screened through identification, eligibility assessment, and inclusion stages. Twelve studies meeting the predefined criteria were included and analyzed qualitatively. The most consistently reported risk factors were poor glycemic control and advanced age. Additional determinants were grouped into metabolic factors (hypertension, dyslipidemia, obesity), lifestyle factors (physical inactivity and smoking), clinical factors (longer diabetes duration and male sex), treatment-related factors (taxane-based chemotherapy, oxaliplatin, and beta-blockers), and sociodemographic factors (race, low educational level, and urban residence). These findings indicate that PN is a multifactorial condition influenced by metabolic, clinical, therapeutic, lifestyle, and social determinants. Peripheral neuropathy is associated with a broad range of modifiable and non-modifiable risk factors, with poor glycemic control and advanced age emerging as the most consistent determinants. Early identification of these factors may support targeted screening, prevention strategies, and risk reduction interventions in clinical practice and public health settings. Future longitudinal studies are needed to clarify causal relationships and improve risk prediction models.
References
Abdissa, D., Hamba, N., Kene, K., Bedane, D.A., Etana, G., Muleta, D., & Gerbi, A. (2020). Prevalence and Determinants of Peripheral Neuropathy among Type 2 Adult Diabetes Patients Attending Jimma University Medical Center, Southwest Ethiopia, 2019: An Institution-Based Cross-Sectional Study. Journal of Diabetes Research, 2020(1), 9562920. https://doi.org/https://doi.org/10.1155/2020/9562920
Braffett, B. H., Gubitosi-Klug, R., Albers, J., Feldman, E., Martin, C., White, N., Orchard, T., Lopes-Virella, M., Lachin, J., Pop-Busui, R., & Group, the DR (2020). Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 69(5), 1000–1010. https://doi.org/10.2337/db19-1046
Cheng, Y., Cao, W., Zhang, J., Wang, J., Liu, X., Wu, Q., & Lin, Q. (2022). Determinants of Diabetic Peripheral Neuropathy and Their Clinical Significance: A Retrospective Cohort Study. Frontiers in Endocrinology, Volume 13. https://doi.org/10.3389/fendo.2022.934020
Chew, S. M., Dua Avinashi, S., & Venkataraman, K. (2025). Predictors of incident diabetic peripheral neuropathy: a systematic review of longitudinal studies in patients with diabetes mellitus. Reviews in Endocrine & Metabolic Disorders, 26(4), 659–677. https://doi.org/10.1007/s11154-025-09973-6
D'Souza, R.S., Saini, C., Hussain, N., Javed, S., Prokop, L., & Her, Y.F. (2025). Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000-24. Regional Anesthesia and Pain Medicine. https://doi.org/10.1136/rapm-2024- 106229
Gebabo, T.F., Zewdie, T., Shagaro, SS, & Haile, F. (2021). Determinants of peripheral neuropathy among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo and Gofa zones, southern Ethiopia. PLOS ONE, 16(2), e0246722. https://doi.org/10.1371/journal.pone.0246722
Hicks, C.W., Wang, D., Matsushita, K., Windham, B.G., & Selvin, E. (2021). Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study. Annals of Internal Medicine, 174(2), 167–174. https://doi.org/10.7326/M20-1340
Hicks, C.W., Wang, D., Windham, B.G., Matsushita, K., & Selvin, E. (2021). Prevalence of peripheral neuropathy determined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Scientific Reports, 11(1), 19159. https://doi.org/10.1038/s41598-021-98565-w
Kamgar, M., Greenwald, M., Assad, H., Hastert, T., McLaughlin, E., Reding, K., Paskett, E., Bea, J., Shadyab, A., Neuhouser, M. L., Nassir, R., Crane, T. E., Sreeram, K., & Simon, MS (2021). Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Medicine, 10 (19), 6666–6676. https://doi.org/https://doi.org/10.1002/cam4.4202
Levitt Katz L, White N, Ghormli L, Chan C, Copeland K, Lipman T, Marcus M, ZP (2021). Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. Diabetes Care, 45(5), 1065–1072. https://doi.org/10.2337/dc21-1074
Lu, Y., Xing, P., Cai, X., Luo, D., Li, R., Lloyd, C., Sartorius, N., & Li, M. (2020). Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study. Frontiers in Public Health, 8 (October), 1–8. https://doi.org/10.3389/fpubh.2020.534372
Pfannkuche, A., Alhajjar, A., Ming, A., Walter, I., Piehler, C., & Mertens, P.R. (2020). Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves.” Endocrine and Metabolic Science, 1(1), 100053. https://doi.org/10.1016/j.endmts.2020.100053
Rodriguez-Saldana, J., Mijangos, J.H.S., Hancock, C.N., Ramsey, D.L., & Weiser, L.-K. (2024). Prevalence and disease burden of peripheral neuropathy in the general population in Mexico city: a cross-sectional epidemiological study. Current Medical Research and Opinion, 40(6), 977–987. https://doi.org/10.1080/03007995.2024.2352852
Savelieff, M.G., Elafros, M.A., Viswanathan, V., Jensen, T.S., Bennett, D.L., & Feldman, E.L. (2025). The global and regional burden of diabetic peripheral neuropathy. Nature Reviews. Neurology, 21(1), 17–31. https://doi.org/10.1038/s41582-024-01041-y
Sun, J., Wang, Y., Zhang, X., Zhu, S., & He, H. (2020). Prevalence of peripheral neuropathy in patients with diabetes: A systematic review and meta-analysis. Primary Care Diabetes, 14(5), 435–444. https://doi.org/10.1016/j.pcd.2019.12.005
Susanti, I., Seraph, N., Edward, M., & Burhan, A. (2025). National Trends in the Prevalence of Diabetic Peripheral Neuropathy Among Diabetes Mellitus Patients in Indonesia (2010–2024): A Pooled Meta-Analysis of 46 Studies with 2,808 Participants. Java Nursing Journal, 3 , 2988–4152. https://doi.org/10.61716/jnj.v3i2.103
Wu, B., Niu, Z., & Hu, F. (2021). Study on Risk Factors of Peripheral Neuropathy in Type 2 Diabetes Mellitus and Establishment of Prediction Model. Dmj, 45(4), 526–538. https://doi.org/10.4093/dmj.2020.0100
Yildirim, N., & Cengiz, M. (2020). Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. Supportive Care in Cancer, 28(10), 4781–4788. https://doi.org/10.1007/s00520-020-05319-x
Zhu, J., Hu, Z., Luo, Y., Liu, Y., Luo, W., Du, X., Luo, Z., Hu, J., & Peng, S. (2024). Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in Endocrinology, Volume 14 - 2023. https://doi.org/10.3389/fendo.2023.1265372
Downloads
Published
Issue
Section
License
Copyright (c) 2026 I Made Putra Biantara, I Wayan Tunjung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as this can lead to productive exchanges and earlier and greater citations of published work.
